Lupin launches authorized generic version of Ravicti in United States

24 Oct 2025 Evaluate

Lupin has launched an authorized generic version of Ravicti (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States. Glycerol Phenylbutyrate Oral Liquid, 1.1g/mL is indicated for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2100.85 8.90 (0.43%)
05-Dec-2025 15:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.15
Dr. Reddys Lab 1275.50
Cipla 1521.80
Zydus Lifesciences 931.80
Lupin 2100.85
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×